The microenvironment of cervical carcinoma xenografts: Associations with lymph node metastasis and its assessment by DCE-MRI

Translational Oncology

Volumn 6, Issue 5, 2013, Pages 607-617

  Ellingsen, Christine ^a   Walenta, Stefan ^b   Hompland, Tord ^a   Mueller Klieser, Wolfgang ^b   Rofstad, Einar K ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; GADOLINIUM PENTETATE; GLUCOSE; LACTIC ACID; PIMONIDAZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CATHETER; CELL HETEROGENEITY; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; TISSUE PRESSURE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA;

EID: 84885718969     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13313     Document Type: Article

References (60)

1. Barbera L and Thomas G (2009). Management of early and locally advanced cervical cancer. Semin Oncol 36, 155-169.
2. Al-Mansour Z and Verschraegen C (2010). Locally advanced cervical cancer: what is the standard of care? Curr Opin Oncol 22, 503-512.
3. Green J, Kirwan J, Tierney J, Vale C, Symonds P, Fresco L, Williams C, and Collingwood M (2005). Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 3, CD002225.
4. Klopp AH and Eifel PJ (2012). Biological predictors of cervical cancer response to radiation therapy. Semin Radiat Oncol 22, 143-150.
5. Höckel M and Vaupel P (2001). Biological consequences of tumor hypoxia. Semin Oncol 2(suppl 8), 36-41.
6. Vaupel PW and Kelleher DK (2012). Blood flow and associated pathophysiology of uterine cervix cancers: characterisation and relevance for localised hyperthermia. Int J Hyperthermia 28, 518-527.
7. 2predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26, 45-50.
8. Höckel M, Schlenger K, Aral B, Mitze M, Schäffer U, and Vaupel P (1996). Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56, 4509-4515.
9. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, Chapman W, Levin W, Manchul L, Keane TJ, et al. (1998). Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48, 149-156.
10. Sundfør K, Lyng H, Tropé CG, and Rofstad EK (2000). Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: relationships to pretreatment tumor oxygenation and vascularization. Radiother Oncol 54, 101-107.
11. Milosevic M, Fyles A, Hedley D, Pintilie M, Levin W, Manchul L, and Hill R (2001). Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res 61, 6400-6405.
12. Fyles A, Milosevic M, Pintilie M, Syed A, Levin W, Manchul L, and Hill RP (2006). Long-term performance of interstitial fluid pressure and hypoxia as prognostic factors in cervix cancer. Radiother Oncol 80, 132-137.
13. Yeo SG, Kim JS, Cho MJ, Kim KH, and Kim JS (2009). Interstitial fluid pressure as a prognostic factor in cervical cancer following radiation therapy. Clin Cancer Res 15, 6201-6207.
14. Schwickert G, Walenta S, Sundfør K, Rofstad EK, and Mueller-Klieser W (1995). Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res 55, 4757-4759.
15. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfør K, Rofstad EK, and Mueller-Klieser W (2000). High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 60, 916-921.
16. Gillies RJ, Raghunand N, Karczmar GS, and Bhujwalla ZM (2002). MRI of the tumor microenvironment. J Magn Reson Imaging 16, 430-450.
17. Hylton N (2006). Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 24, 3293-3298.
18. Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, and Tan LT (2007). Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol 8, 63-74.
19. Yuh WTC, Mayr NA, Jarjoura D, Wu D, Grecula JC, Lo SS, Edwards SM, Magnotta VA, Sammet S, Zhang H, et al. (2009). Predicting control of primary tumor and survival by DCE MRI during early therapy in cervical cancer. Invest Radiol 44, 343-350.
20. Hawighorst H, Weikel W, Knapstein PG, Knopp MV, Zuna I, Schoenberg SO, Vaupel P, and van Kaick G (1998). Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res 4, 2305-2312.
21. Donaldson SB, Buckley DL, O'Connor JP, Davidson SE, Carrington BM, Jones AP, and West CML (2010). Enhancing fraction measured using dynamic contrast-enhanced MRI predicts disease-free survival in patients with carcinoma of the cervix. Br J Cancer 102, 23-26.
22. Mayr NA, Wang JZ, Zhang D, Montebello JF, Grecula JC, Lo SS, Fowler JF, and Yuh WTC (2009). Synergistic effects of hemoglobin and tumor perfusion on tumor control and survival in cervical cancer. Int J Radiat Oncol Biol Phys 74, 1513-1521.
23. Andersen EKF, Hole KH, Lund KV, Sundfør K, Kristensen GB, Lyng H, and Malinen E (2012). Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance. Int J Radiat Oncol Biol Phys 82, e485-e492.
24. Lyng H, Vorren AO, Sundfør K, Taksdal I, Lien HH, Kaalhus O, and Rofstad EK (2001). Assessment of tumor oxygenation in human cervical carcinoma by use of dynamic Gd-DTPA-enhanced MR imaging. J Magn Reson Imaging 14, 750-756.
25. Hawighorst H, Knapstein PG, Weikel W, Knopp MV, Zuna I, Knof A, Brix G, Schaeffer U, Wilkens C, Schoenberg SO, et al. (1997). Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res 57, 4777-4786.
26. Cooper RA, Carrington BM, Loncaster JA, Todd SM, Davidson SE, Logue JP, Luthra AD, Jones AP, Stratford I, Hunter RD, et al. (2000). Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 57, 53-59.
27. Ellingsen C, Natvig I, Gaustad JV, Gulliksrud K, Egeland TAM, and Rofstad EK (2009). Human cervical carcinoma xenograft models for studies of the physiological microenvironment of tumors. J Cancer Res Clin Oncol 135, 1177-1184.
28. Gulliksrud K, Øvrebø KM, Mathiesen B, and Rofstad EK (2011). Differentiation between hypoxic and non-hypoxic experimental tumors by dynamic contrast-enhanced magnetic resonance imaging. Radiother Oncol 98, 360-364.
29. Egeland TAM, Gulliksrud K, Gaustad JV, Mathiesen B, and Rofstad EK (2012). Dynamic contrast-enhanced MRI of tumor hypoxia. Magn Reson Med 67, 519-530.
30. Hittmair K, Gomiscek G, Langenberger K, Recht M, Imhof H, and Kramer J (1994). Method for the quantitative assessment of contrast agent uptake in dynamic contrast-enhanced MRI. Magn Reson Med 31, 567-571.
31. Benjaminsen IC, Graff BA, Brurberg KG, and Rofstad EK (2004). Assessment of tumor blood perfusion by high-resolution dynamic contrast-enhanced MRI: a preclinical study of human melanoma xenografts. Magn Reson Med 52, 269-276.
32. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HBW, Lee T-Y, Mayr NA, Parker GJM, et al. (1999). Estimating kinetic parameters from dynamic contrast-enhanced T 1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10, 223-232.
33. Ozerdem U and Hargens AR (2005). A simple method for measuring interstitial fluid pressure in cancer tissues. Microvasc Res 70, 116-120.
34. Rofstad EK and Måseide K (1999). Radiobiological and immunohistochemical assessment of hypoxia in human melanoma xenografts: acute and chronic hypoxia in individual tumours. Int J Radiat Biol 75, 1377-1393.
35. Rofstad EK, Galappathi K, Mathiesen B, and Ruud EBM (2007). Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis. Clin Cancer Res 13, 1971-1978.
36. Walenta S, Schroeder T, and Mueller-Klieser W (2002). Metabolic mapping with bioluminescence: basic and clinical relevance. Biomol Eng 18, 249-262.
37. Walenta S, Schroeder T, and Mueller-Klieser W (2004). Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Curr Med Chem 11, 2195-2204.
38. Sattler UG, Walenta S, and Mueller-Klieser W (2007). A bioluminescence technique for quantitative and structure-associated imaging of pyruvate. Lab Invest 87, 84-92.
39. Mueller-Klieser W and Walenta S (1993). Geographical mapping of metabolites in biological tissue with quantitative bioluminescence and single photon imaging. Histochem J 25, 407-420.
40. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, and Thompson CB (2007). Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104, 19345-19350.
41. Vaupel P, Kallinowski F, and Okunieff P (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49, 6449-6465.
42. Gulledge CJ and Dewhirst MW (1996). Tumor oxygenation: a matter of supply and demand. Anticancer Res 16, 741-750.
43. Gatenby RA and Gillies RJ (2004). Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4, 891-899.
44. 2fluctuation pattern and cycling hypoxia in human cervical carcinoma and melanoma xenografts. Int J Radiat Oncol Biol Phys 83, 1317-1323.
45. Kroeger M, Walenta S, Rofstad EK, and Mueller-Klieser W (1995). Growth rates or radiobiological hypoxia are not correlated with local metabolite content in human melanoma xenografts with similar vascular network. Br J Cancer 72, 912-916.
46. Walenta S, Snyder S, Haroon ZA, Braun RD, Amin K, Brizel D, Mueller-Klieser W, Chance B, and Dewhirst MW (2001). Tissue gradients of energy metabolites mirror oxygen tension gradients in a rat mammary carcinoma model. Int J Radiat Oncol Biol Phys 51, 840-848.
47. Schroeder T, Yuan H, Viglianti BL, Peltz C, Asopa S, Vujaskovic Z, and Dewhirst MW(2005). Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. Cancer Res 65, 5163-5171.
48. Yaromina A, Quennet V, Zips D, Meyer S, Shakirin G, Walenta S, Mueller-Klieser W, and Baumann M (2009). Co-localisation of hypoxia and perfusion markers with parameters of glucose metabolism in human squamous cell carcinoma (hSCC) xenografts. Int J Radiat Biol 85, 972-980.
49. Walenta S and Mueller-Klieser W (2004). Lactate: mirror and motor of tumor malignancy. Semin Radiat Oncol 14, 267-274.
50. Busk M, Horsman MR, Kristjansen PEG, van der Kogel AJ, Bussink J, and Overgaard J (2008). Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer 122, 2726-2734.
51. Rofstad EK (2000). Microenvironment-induced cancer metastasis. Int J Radiat Biol 76, 589-605.
52. Lunt SJ, Chaudary N, and Hill RP (2009). The tumor microenvironment and metastatic disease. Clin Exp Metastasis 26, 19-34.
53. Chan DA and Giaccia A (2007). Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 26, 333-339.
54. Hirschhaeuser F, Sattler UGA, and Mueller-Klieser W (2011). Lactate: a metabolic key player in cancer. Cancer Res 71, 6921-6925.
55. Rutkowski JM and Swartz MA (2007). A driving force for change: interstitial flow as a morphoregulator. Trends Cell Biol 17, 44-50.
56. Mumprecht V and Detmar M (2009). Lymphangiogenesis and cancer metastasis. J Cell Mol Med 13, 1405-1416.
57. Hompland T, Ellingsen C, Galappathi K, and Rofstad EK (2013). Connective tissue of cervical carcinoma xenografts: associations with tumor hypoxia and interstitial fluid pressure and its assessment by DCE-MRI and DW-MRI. Acta Oncol, Epub ahead of print February 27.
58. Hallac RR, Ding Y, Yuan Q, McColl RW, Lea J, Sims RD, Weatherall PT, and Mason RP (2012). Oxygenation in cervical cancer and normal uterine cervix assessed using blood oxygenation level-dependent (BOLD) MRI at 3T. NMR Biomed 25, 1321-1330.
59. Hompland T, Ellingsen C, Øvrebø KM, and Rofstad EK (2012). Interstitial fluid pressure and associated lymph node metastasis revealed in tumors by dynamic contrast-enhanced MRI. Cancer Res 72, 4899-4908.
60. Serganova I, Rizwan A, Ni X, Thakur SB, Vider J, Russell J, Blasberg R, and Koutcher JA (2011). Metabolic imaging: a link between lactate dehydrogenase A, lactate, and tumor phenotype. Clin Cancer Res 17, 6250-6261.